Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes

A Multicenter, Open Label, Long-Term Safety Study of 52 Weeks Treatment With Vildagliptin in Patients With Type 2 Diabetes

This study is designed to demonstrate the long-term safety of vildagliptin in patients with type 2 diabetes. This study will study vildagliptin as add-on therapy with metformin, thiazolidinedione, α-glucosidase inhibitor (α-GI), rapid-acting insulin secretagogues in the treatment of type 2 diabetes in Japan.

Inclusion Criteria:

• patients with type 2 diabetes inadequately controlled with diet, exercise and metformin, thiazolidinedione, or α-GI, or glinides monotherapy
• Age in the 20 years or over inclusive
• HbA1c in the range of ≥ 6.5 to ≤ 10%

Exclusion Criteria:

• Type 1 diabetes mellitus, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
• Significant heart diseases
• Significant diabetic complications